Dr. Barbara Burtness, MD
Claim this profileYale University
Studies Squamous Cell Carcinoma
Studies Skin Cancer
9 reported clinical trials
18 drugs studied
Area of expertise
1Squamous Cell Carcinoma
Stage III
Stage IV
HPV negative
2Skin Cancer
Stage III
Stage IV
Carcinoma of the neck
Affiliated Hospitals
Clinical Trials Barbara Burtness, MD is currently running
5-Azacytidine + Nivolumab
for Squamous Cell Carcinoma
This study is being done because both 5-azacytidine and nivolumab can influence the immune system's response to HPV-associated head and neck cancer, and we wish to evaluate whether taking 5-azacytidine will make HPV-associated head and neck cancer more sensitive to treatment with nivolumab. 5-Azacytidine (5-AZA) is a chemotherapy, and nivolumab is an immunotherapy. Both drugs are approved for use in the US by the Food and Drug Administration (FDA) for use in the treatment of different types of cancer, and nivolumab is approved for use in head and neck cancer that has previously been treated with chemotherapy. Because they are not approved to be used together in HPV-associated head and neck cancer, these drugs are considered experimental in this study. For this study, the drugs will be used either together or separately.
Recruiting1 award Phase 2
Radiation Therapy + Cisplatin
for Head and Neck Cancer
This trial is studying if using a specific type of energy treatment alone or with a drug is better for treating patients with advanced head and neck cancer after surgery. The energy treatment kills cancer cells, and the drug helps by stopping their growth or killing them. The drug has been used for many years in the treatment of advanced cancers, including head and neck cancers, and is known for its ability to enhance the effects of the energy treatment.
Recruiting1 award Phase 219 criteria
More about Barbara Burtness, MD
Clinical Trial Related1 year of experience running clinical trials · Led 9 trials as a Principal Investigator · 6 Active Clinical TrialsTreatments Barbara Burtness, MD has experience with
- Cisplatin
- Dostarlimab
- Intensity-Modulated Radiation Therapy
- 5-azacytidine
- Combination 5-azacytidine And Nivolumab
- Nivolumab
Breakdown of trials Barbara Burtness, MD has run
Squamous Cell Carcinoma
Skin Cancer
Head and Neck Squamous Cell Carcinoma
Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Barbara Burtness, MD specialize in?
Barbara Burtness, MD focuses on Squamous Cell Carcinoma and Skin Cancer. In particular, much of their work with Squamous Cell Carcinoma has involved Stage III patients, or patients who are Stage IV.
Is Barbara Burtness, MD currently recruiting for clinical trials?
Yes, Barbara Burtness, MD is currently recruiting for 6 clinical trials in New Haven Connecticut. If you're interested in participating, you should apply.
Are there any treatments that Barbara Burtness, MD has studied deeply?
Yes, Barbara Burtness, MD has studied treatments such as Cisplatin, Dostarlimab, Intensity-Modulated Radiation Therapy.
What is the best way to schedule an appointment with Barbara Burtness, MD?
Apply for one of the trials that Barbara Burtness, MD is conducting.
What is the office address of Barbara Burtness, MD?
The office of Barbara Burtness, MD is located at: Yale University, New Haven, Connecticut 06511 United States. This is the address for their practice at the Yale University.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.